Rep. John E. Bradley

Filed: 4/1/2009

 

 


 

 


 
09600HB1967ham001 LRB096 05326 RLC 25002 a

1
AMENDMENT TO HOUSE BILL 1967

2     AMENDMENT NO. ______. Amend House Bill 1967 by replacing
3 everything after the enacting clause with the following:
 
4     "Section 5. The Illinois Controlled Substances Act is
5 amended by changing Sections 317 and 318 as follows:
 
6     (720 ILCS 570/317)
7     Sec. 317. Central repository for collection of
8 information.
9     (a) The Department must designate a central repository for
10 the collection of information transmitted under Section 316 and
11 321.
12     (b) The central repository must do the following:
13         (1) Create a database for information required to be
14     transmitted under Section 316 in the form required under
15     rules adopted by the Department, including search
16     capability for the following:

 

 

09600HB1967ham001 - 2 - LRB096 05326 RLC 25002 a

1             (A) A recipient's name.
2             (B) A recipient's address.
3             (C) The national drug code number of a controlled
4         substance dispensed.
5             (D) The dates a controlled substance is dispensed.
6             (E) The quantities of a controlled substance
7         dispensed.
8             (F) A dispenser's United States Drug Enforcement
9         Administration registration number.
10             (G) A prescriber's United States Drug Enforcement
11         Administration registration number.
12         (2) Provide the Department with a database maintained
13     by the central repository. The Department of Financial and
14     Professional Regulation must provide the Department with
15     electronic access to the license information of a
16     prescriber or dispenser. The Department of Financial and
17     Professional Regulation may charge a fee for this access
18     not to exceed the actual cost of furnishing the
19     information.
20         (3) Secure the information collected by the central
21     repository and the database maintained by the central
22     repository against access by unauthorized persons.
23     (c) The Department must retain the information in the
24 central repository for at least 90 days.
25     No fee shall be charged for access by a prescriber or
26 dispenser.

 

 

09600HB1967ham001 - 3 - LRB096 05326 RLC 25002 a

1 (Source: P.A. 95-442, eff. 1-1-08.)
 
2     (720 ILCS 570/318)
3     Sec. 318. Confidentiality of information.
4     (a) Information received by the central repository under
5 Section 316 and 321 is confidential.
6     (b) The Department must carry out a program to protect the
7 confidentiality of the information described in subsection
8 (a). The Department may disclose the information to another
9 person only under subsection (c), (d), or (f) and may charge a
10 fee not to exceed the actual cost of furnishing the
11 information.
12     (c) The Department may disclose confidential information
13 described in subsection (a) to any person who is engaged in
14 receiving, processing, or storing the information.
15     (d) The Department may release confidential information
16 described in subsection (a) to the following persons:
17         (1) A governing body that licenses practitioners and is
18     engaged in an investigation, an adjudication, or a
19     prosecution of a violation under any State or federal law
20     that involves a controlled substance.
21         (2) An investigator for the Consumer Protection
22     Division of the office of the Attorney General, a
23     prosecuting attorney, the Attorney General, a deputy
24     Attorney General, or an investigator from the office of the
25     Attorney General, who is engaged in any of the following

 

 

09600HB1967ham001 - 4 - LRB096 05326 RLC 25002 a

1     activities involving controlled substances:
2             (A) an investigation;
3             (B) an adjudication; or
4             (C) a prosecution of a violation under any State or
5         federal law that involves a controlled substance.
6         (3) A law enforcement officer who is:
7             (A) authorized by the Department of State Police or
8         the office of a county sheriff or State's Attorney or
9         municipal police department of Illinois to receive
10         information of the type requested for the purpose of
11         investigations involving controlled substances; or
12             (B) approved by the Department to receive
13         information of the type requested for the purpose of
14         investigations involving controlled substances; and
15             (C) engaged in the investigation or prosecution of
16         a violation under any State or federal law that
17         involves a controlled substance.
18     (e) Before the Department releases confidential
19 information under subsection (d), the applicant must
20 demonstrate in writing to the Department that:
21         (1) the applicant has reason to believe that a
22     violation under any State or federal law that involves a
23     controlled substance has occurred; and
24         (2) the requested information is reasonably related to
25     the investigation, adjudication, or prosecution of the
26     violation described in subdivision (1).

 

 

09600HB1967ham001 - 5 - LRB096 05326 RLC 25002 a

1     The provisions of this subsection (e) do not apply to a law
2 enforcement officer authorized to obtain access to the
3 confidential information under subparagraph (A) of paragraph
4 (3) of subsection (d) of this Section.
5     (f) The Department may receive and release prescription
6 record information to:
7         (1) a governing body that licenses practitioners;
8         (2) an investigator for the Consumer Protection
9     Division of the office of the Attorney General, a
10     prosecuting attorney, the Attorney General, a deputy
11     Attorney General, or an investigator from the office of the
12     Attorney General;
13         (3) any Illinois law enforcement officer who is:
14             (A) authorized to receive the type of information
15         released; and
16             (B) (blank) approved by the Department to receive
17         the type of information released; or
18         (4) prescription monitoring entities in other states
19     per the provisions outlined in subsection (g) and (h)
20     below;
21 confidential prescription record information collected under
22 Sections 316 and 321 that identifies vendors or practitioners,
23 or both, who are prescribing or dispensing large quantities of
24 Schedule II, III, IV, or V controlled substances outside the
25 scope of their practice, pharmacy, or business, as determined
26 by the Advisory Committee created by Section 320.

 

 

09600HB1967ham001 - 6 - LRB096 05326 RLC 25002 a

1     (g) The information described in subsection (f) may not be
2 released until it has been reviewed by an employee of the
3 Department who is licensed as a prescriber or a dispenser and
4 until that employee has certified that further investigation is
5 warranted. However, failure to comply with this subsection (g)
6 does not invalidate the use of any evidence that is otherwise
7 admissible in a proceeding described in subsection (h).
8     (h) An investigator or a law enforcement officer receiving
9 confidential information under subsection (c), (d), or (f) may
10 disclose the information to a law enforcement officer or an
11 attorney for the office of the Attorney General for use as
12 evidence in the following:
13         (1) A proceeding under any State or federal law that
14     involves a controlled substance.
15         (2) A criminal proceeding or a proceeding in juvenile
16     court that involves a controlled substance.
17     (i) The Department may compile statistical reports from the
18 information described in subsection (a). The reports must not
19 include information that identifies, by name, license or
20 address, any practitioner, dispenser, ultimate user, or other
21 person administering a controlled substance.
22     (j) Based upon federal, initial and maintenance funding, a
23 prescriber and dispenser inquiry system shall be developed to
24 assist the medical community in its goal of effective clinical
25 practice and to prevent patients from diverting or abusing
26 medications.

 

 

09600HB1967ham001 - 7 - LRB096 05326 RLC 25002 a

1         (1) An inquirer shall have read-only access to a
2     stand-alone database which shall contain records for the
3     previous 6 months.
4         (2) Dispensers may, upon positive and secure
5     identification, make an inquiry on a patient or customer
6     solely for a medical purpose as delineated within the
7     federal HIPAA law.
8         (3) The Department shall provide a one-to-one secure
9     link and encrypted software necessary to establish the link
10     between an inquirer and the Department. Technical
11     assistance shall also be provided.
12         (4) Written inquiries are acceptable but must include
13     the fee and the requestor's Drug Enforcement
14     Administration license number and submitted upon the
15     requestor's business stationary.
16         (5) No data shall be stored in the database beyond 24
17     months.
18         (6) Tracking analysis shall be established and used per
19     administrative rule.
20         (7) Nothing in this Act or Illinois law shall be
21     construed to require a prescriber or dispenser to make use
22     of this inquiry system.
23         (8) If there is an adverse outcome because of a
24     prescriber or dispenser making an inquiry, which is
25     initiated in good faith, the prescriber or dispenser shall
26     be held harmless from any civil liability.

 

 

09600HB1967ham001 - 8 - LRB096 05326 RLC 25002 a

1 (Source: P.A. 95-442, eff. 1-1-08.)".